AAV TERT03
Alternative Names: AAV-TERT-03Latest Information Update: 09 Oct 2025
At a glance
- Originator Telomere Therapeutics
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Unspecified
Most Recent Events
- 09 Sep 2025 Early research in Unspecified in Spain (Parenteral) before September 2025 (Telomere Therapeutics pipeline, September 2025)